101 related articles for article (PubMed ID: 29285361)
1. Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report.
Mizutani K; Horie K; Nagai S; Tsuchiya T; Saigo C; Kobayashi K; Miyazaki T; Deguchi T
Mol Clin Oncol; 2017 Dec; 7(6):988-990. PubMed ID: 29285361
[TBL] [Abstract][Full Text] [Related]
2. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
[TBL] [Abstract][Full Text] [Related]
3. Large cell neuroendocrine carcinoma of the lung that responded to nivolumab: A case report.
Takimoto Sato M; Ikezawa Y; Sato M; Suzuki A; Kawai Y
Mol Clin Oncol; 2020 Jul; 13(1):43-47. PubMed ID: 32499913
[TBL] [Abstract][Full Text] [Related]
4. Rapid progression of recurrent disease in a patient with renal cell carcinoma with vaginal metastasis.
Hisano M; Kato R; Itamochi H; Matsuura T; Maekawa S; Kato Y; Kanehira M; Takata R; Baba T; Obara W
IJU Case Rep; 2020 Sep; 3(5):185-188. PubMed ID: 32914070
[TBL] [Abstract][Full Text] [Related]
5. Long-term Response to Nivolumab and Acute Renal Failure in a Patient with Metastatic Papillary Renal Cell Carcinoma and a PD-L1 Tumor Expression Increased with Sunitinib Therapy: A Case Report.
Ruiz-Bañobre J; Anido U; Abdulkader I; Antúnez-López J; López-López R; García-González J
Front Oncol; 2016; 6():250. PubMed ID: 27921007
[TBL] [Abstract][Full Text] [Related]
6. Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma.
Nakajima N; Kano T; Oda K; Uchida T; Otaki T; Nagao K; Shimizu Y; Kawakami M; Kim H; Nitta M; Hasegawa M; Kawamura Y; Miyajima A
IJU Case Rep; 2020 Sep; 3(5):215-218. PubMed ID: 32914080
[TBL] [Abstract][Full Text] [Related]
7. Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma.
Hagimoto H; Kashima S; Doi K; Nakayama S; Sano T; Imai S; Yasufuku T; Muramaki M; Yamada Y
IJU Case Rep; 2020 Nov; 3(6):287-290. PubMed ID: 33163928
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab as a Promising Treatment Option for Metastatic Salivary Duct Carcinoma.
Bugia L; Jungbauer F; Zaubitzer L; Hörner C; Merx K; Yasser AM; Germann T; Lammert A; Scherl C; Rotter N; Affolter A
J Immunother; 2024 Mar; ():. PubMed ID: 38545827
[TBL] [Abstract][Full Text] [Related]
9. Effect of rechallenge nivolumab in a hemodialysis patient with multiple metastases from a rapidly progressed T1a renal clear cell carcinoma: An autopsy case.
Hanawa K; Sawada N; Yokota Y; Aikawa J; Otake Y; Sugimura K; Shimura H; Mochizuki T; Kira S; Mitsui T
IJU Case Rep; 2024 May; 7(3):202-205. PubMed ID: 38686062
[TBL] [Abstract][Full Text] [Related]
10. Durable complete response to immunotherapy with anti-PD-1 antibody nivolumab in a patient with oral squamous cell carcinoma presenting with lung metastasis: A case report.
Sekido K; Imaue S; Tomihara K; Tachinami H; Yamagishi K; Okazawa S; Ikeda A; Fujiwara K; Noguchi M
Clin Case Rep; 2021 Sep; 9(9):e04545. PubMed ID: 34484745
[TBL] [Abstract][Full Text] [Related]
11. A complete response to Pembrolizumab for metastatic collecting duct carcinoma of the kidney.
Abe S; Inoue T; Hata S; Shibuya T; Ando T; Shin T
Urol Case Rep; 2024 Mar; 53():102662. PubMed ID: 38444618
[TBL] [Abstract][Full Text] [Related]
12. Effective treatment of gallbladder neuroendocrine carcinoma with nivolumab.
Kanda S; Hiyama K; Kirino I; Fukui Y; Terashima H
Clin Case Rep; 2023 Oct; 11(10):e8040. PubMed ID: 37841882
[TBL] [Abstract][Full Text] [Related]
13. Editorial Comment from Dr Kobayashi to Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma.
Kobayashi T
IJU Case Rep; 2020 Nov; 3(6):292. PubMed ID: 33163930
[No Abstract] [Full Text] [Related]
14. Editorial comment from Dr Yuasa to Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma.
Yuasa T
IJU Case Rep; 2020 Nov; 3(6):291. PubMed ID: 33163929
[No Abstract] [Full Text] [Related]
15. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.
Koshkin VS; Barata PC; Zhang T; George DJ; Atkins MB; Kelly WJ; Vogelzang NJ; Pal SK; Hsu J; Appleman LJ; Ornstein MC; Gilligan T; Grivas P; Garcia JA; Rini BI
J Immunother Cancer; 2018 Jan; 6(1):9. PubMed ID: 29378660
[TBL] [Abstract][Full Text] [Related]
16. Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71].
Escudier B; Sharma P; McDermott DF; George S; Hammers HJ; Srinivas S; Tykodi SS; Sosman JA; Procopio G; Plimack ER; Castellano D; Gurney H; Donskov F; Peltola K; Wagstaff J; Gauler TC; Ueda T; Zhao H; Waxman IM; Motzer RJ;
Eur Urol; 2018 Apr; 73(4):e116-e118. PubMed ID: 29306512
[No Abstract] [Full Text] [Related]
17. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
Tan PS; Aguiar P; Haaland B; Lopes G
Lung Cancer; 2018 Jan; 115():84-88. PubMed ID: 29290267
[TBL] [Abstract][Full Text] [Related]
19. Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report.
Hakozaki T; Okuma Y; Kashima J
BMC Cancer; 2018 Mar; 18(1):302. PubMed ID: 29554874
[TBL] [Abstract][Full Text] [Related]
20. Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients.
Garde-Noguera J; Martin-Martorell P; De Julián M; Perez-Altozano J; Salvador-Coloma C; García-Sanchez J; Insa-Molla A; Martín M; Mielgo-Rubio X; Marin-Liebana S; Blasco-Cordellat A; Blasco-Molla S; Gironés R; Marquez-Medina D; Aparisi F; Cerda MCB; Macia-Escalante S; Sánchez A; Juan-Vidal O
Clin Transl Oncol; 2018 Aug; 20(8):1072-1079. PubMed ID: 29368144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
